MPI-CDG | Rare Diseases Clinical Research Network

Researchers Establish New Consensus Guidelines for Congenital Disorders of Glycosylation Dakota Campbell Mon, 12/07/2020 - 11:11

Health care providers now have a road map for treating two types of congenital disorders of glycosylation: MPI-CDG and PGM1-CDG. A team of international experts from the Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC) published new guidelines for the diagnosis and management of MPI-CDG and PGM1-CDG in the Journal of Inherited Metabolic Disease.

Frontiers in Congenital Disorders of Glycosylation Consortium

FCDGC

MPI-CDG

PGM1-CDG

Subscribe to MPI-CDG

The Rare Diseases Clinical Research Network (RDCRN) is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Office of Rare Diseases Research (ORDR). The RDCRN websites are hosted by the network’s Data Management and Coordinating Center at Cincinnati Children’s Hospital Medical Center, which is funded by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS) under grant number TR002818.